The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...
Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback